# Clinical Outcomes of Palbociclib and Fulvestrant in PALOMA-3 ## Palbociclib plus fulvestrant clinical outcomes PALOMA-3 In the PALOMA-3 trial, palbociclib plus fulvestrant improved progression-free survival by approximately 5 months, overall survival by 6.9 months, and doubled time to chemotherapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer progressing on prior endocrine therapy, with a manageable safety profile dominated by reversible hematologic toxicity. # Abstract The PALOMA-3 trial demonstrated substantial clinical benefit for palbociclib plus fulvestrant in hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. Across multiple analyses with follow-up extending to 73.3 months, palbociclib plus fulvestrant consistently improved median progression-free survival by approximately 5 months compared to placebo plus fulvestrant (9.2-11.2 months vs 3.8-4.6 months, HR 0.42-0.50, p<0.001). The most recent analysis showed median overall survival of 34.8 months versus 28.0 months (HR 0.81, 95% CI 0.65-0.99), with greater benefit observed in patients with endocrine-sensitive disease who had not received prior chemotherapy for metastatic disease (39.3 vs 29.7 months, HR 0.72). Palbociclib plus fulvestrant doubled the median time to receipt of chemotherapy (17.6 vs 8.8 months, HR 0.58, p<0.001). The safety profile was characterized by predictable hematologic toxicity, with grade 3-4 neutropenia occurring in 52-65% of patients but febrile neutropenia remaining low at 0.6-4.1%. Treatment discontinuation rates due to adverse events were minimal (2.0-2.6%), and dose intensity was maintained at 89.7% despite frequent dose modifications. Clinical benefit was consistent across menopausal status, geographic populations including Asian patients (HR 0.485), and molecular subtypes, with palbociclib providing benefit regardless of ESR1, PIK3CA, or TP53 mutation status. Quality of life was maintained with no significant deterioration from baseline. ## Methods We analyzed 10 sources from an initial pool of 200, using 8 screening criteria... ## Results ### Characteristics of Included Studies The review included 10 publications reporting results from the PALOMA-3 trial, a randomized, double-blind, phase 3 study evaluating palbociclib plus fulvestrant versus placebo plus fulvestrant in patients with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. | Study | Full text retrieved? | Study focus | Sample size (Palbociclib/Placebo) | Median follow-up | Analysis type | |---------------------------------------|----------------------|------------------------------------|------------------------------------|------------------|------------------------| | M. Cristofanilli et al., 2016 | No | Primary efficacy endpoint (PFS) | 347/174 | 8.9 months | Final analysis | | J. Ro et al., 2015 | No | Primary efficacy endpoint (PFS) | 347/174 | Not mentioned | Interim analysis | | N. Turner et al., 2018 | No | Overall survival analysis | Not mentioned | 44.8 months | Prespecified OS analysis| | N. Turner et al., 2015 | Yes | Primary efficacy endpoint (PFS) | ~347/174 | Not mentioned | Interim analysis | | A. Walker et al., 2016 | No | FDA approval summary | 347/174 | Not mentioned | Regulatory approval | | H. Iwata et al., 2017 | No | Asian subgroup analysis | 71/31 | Not mentioned | Subgroup analysis | | S. Verma et al., 2016 | No | Safety update | ~347/174 | 5.6 months | Updated safety analysis | | M. Cristofanilli et al., 2021 | No | Overall survival update | Not mentioned | Not mentioned | Updated OS analysis | | M. Cristofanilli et al., 2016a | No | Confirmed efficacy and safety | 347/174 | 8.9 months | Updated efficacy analysis| | M. Cristofanilli et al., 2022 | Yes | Long-term OS and biomarkers | 347/174 | 73.3 months | Updated exploratory OS analysis| The PALOMA-3 trial randomized 521 women with hormone receptor-positive, HER2-negative metastatic breast cancer... Palbociclib was administered orally at 125 mg daily for 3 weeks followed by 1 week off over 28-day cycles. Fulvestrant was given at 500 mg intramuscularly on days 1 and 15 of cycle 1, then on day 1 of subsequent 28-day cycles. Pre- and perimenopausal women also received goserelin. ## Progression-Free Survival The primary endpoint of progression-free survival (PFS) showed consistent and substantial improvement with palbociclib plus fulvestrant across multiple analyses. Interim analyses reported median PFS of 9.2 months for palbociclib plus fulvestrant versus 3.8 months for placebo plus fulvestrant (HR 0.42, 95% CI 0.32-0.56, p<0.001)... ## Overall Survival Overall survival (OS) analyses evolved with longer follow-up... ## Time to Subsequent Therapy Palbociclib plus fulvestrant significantly delayed the need for chemotherapy. Median time to receipt of chemotherapy was 17.6 months for palbociclib plus fulvestrant compared to 8.8 months for placebo plus fulvestrant... ## Safety and Tolerability The safety profile of palbociclib plus fulvestrant was characterized predominantly by asymptomatic hematologic toxicity... ## Subgroup Analyses Subgroup analyses demonstrated consistent benefit of palbociclib plus fulvestrant across pre-specified stratification factors. ## Biomarker Analyses Circulating tumor DNA (ctDNA) analysis was performed using a targeted panel of 17 genes in 331 patients at day 1... ## Patient-Reported Outcomes Patient-reported outcomes were assessed as a secondary endpoint... ## Synthesis The PALOMA-3 trial demonstrated consistent and clinically meaningful benefit of adding palbociclib to fulvestrant... ## References 1. [H. Iwata et al., 2017](/content/review/5a2d12d3-3b38-45ed-84e9-75673fd73eee/source/ss-24465916/index.html) - Journal of Global Oncology 2. [M. Cristofanilli et al., 2016](/content/review/5a2d12d3-3b38-45ed-84e9-75673fd73eee/source/ss-206141968/index.html) - The Lancet Oncology 3. [J. Ro et al., 2015](/content/review/5a2d12d3-3b38-45ed-84e9-75673fd73eee/source/ss-496932/index.html) - Journal of Clinical Oncology 4. [S. Verma et al., 2016](/content/review/5a2d12d3-3b38-45ed-84e9-75673fd73eee/source/ss-76854737/index.html) - Cancer Research 5. [M. Cristofanilli et al., 2021](/content/review/5a2d12d3-3b38-45ed-84e9-75673fd73eee/source/ss-236350824/index.html) - Journal of Clinical Oncology 6. [M. Cristofanilli et al., 2022](/content/review/5a2d12d3-3b38-45ed-84e9-75673fd73eee/source/ss-248757160/index.html) - Clinical Cancer Research